Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
Merck, Gilead score in effort to develop the first weekly HIV pill
A combination of Merck’s islatravir and Gilead’s lenacapavir has
597 words~3 min read
Other newsrooms on this story
· 3 sources
biopharmadive.com·
Merck, Gilead report mixed outcomes in key lung cancer, HIV studies
morningstar.com·
Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment
statnews.com·
Gilead and Merck's latest trial success and flop
